PUBLIC COMPANY
savePathos AI Inc
updated 2mo ago
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 2
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →🐶 Hiring Signal
News
- J&J pharma leader to retire; Krystal slumps on gene therapy missJennifer Taubert will step down after a lengthy run leading J&J’s pharmaceutical business. Elsewhere, pricing issues hampered what Wall Street analysts view as an otherwise strong gene therapy launch.biopharma_dive · 10d ago
- Pathos inks back-to-back cancer contracts with AstraZeneca, China’s AlphamabPathos AI could pay more than $2 billion to a Jiangsu Alphamab Biopharmaceuticals subsidiary for a late-stage bispecific antibody-drug conjugate for breast cancer, while the financial details of th…biospace · 11d ago
- Pathos AI pads pipeline with $2.2B Alphamab deal, AstraZeneca pactPathos AI has agreed to pay $125 million for a bispecific antibody-drug conjugate from China’s Alphamab Oncology, while adding a Big Pharma partner in the form of AstraZeneca.fiercebiotech · 11d ago
- Pathos does deals with AstraZeneca, China's Alphamab, seeks up to $300M Series EPathos AI is firing on all cylinders. The technology and drug development company told Endpoints News that it signed a major antibody-drug conjugate deal with a Chinese biotech and teamed up with i…endpoints · 11d ago
Data sources
Found something off?
comments(0)
5-min edit window · permanent after that